iBio, Inc. Statistics
Total Valuation
iBio, Inc. has a market cap or net worth of $11.84 million. The enterprise value is $11.20 million.
Important Dates
The last earnings date was Friday, May 2, 2025, before market open.
| Earnings Date | May 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
iBio, Inc. has 16.22 million shares outstanding. The number of shares has increased by 376.23% in one year.
| Current Share Class | 16.22M |
| Shares Outstanding | 16.22M |
| Shares Change (YoY) | +376.23% |
| Shares Change (QoQ) | +7.99% |
| Owned by Insiders (%) | 2.65% |
| Owned by Institutions (%) | 16.07% |
| Float | 15.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.61 |
| Forward PS | 116.08 |
| PB Ratio | 0.65 |
| P/TBV Ratio | 2.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 29.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.38.
| Current Ratio | 1.12 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -73.74 |
Financial Efficiency
Return on equity (ROE) is -90.83% and return on invested capital (ROIC) is -35.91%.
| Return on Equity (ROE) | -90.83% |
| Return on Assets (ROA) | -30.35% |
| Return on Invested Capital (ROIC) | -35.91% |
| Return on Capital Employed (ROCE) | -122.67% |
| Revenue Per Employee | $23,438 |
| Profits Per Employee | -$1.31M |
| Employee Count | 16 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.07% in the last 52 weeks. The beta is 0.94, so iBio, Inc.'s price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | -65.07% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 2.48 |
| Relative Strength Index (RSI) | 38.43 |
| Average Volume (20 Days) | 5,122,059 |
Short Selling Information
The latest short interest is 633,804, so 3.91% of the outstanding shares have been sold short.
| Short Interest | 633,804 |
| Short Previous Month | 1.73M |
| Short % of Shares Out | 3.91% |
| Short % of Float | 4.08% |
| Short Ratio (days to cover) | 0.80 |
Income Statement
In the last 12 months, iBio, Inc. had revenue of $375,000 and -$20.99 million in losses. Loss per share was -$2.32.
| Revenue | 375,000 |
| Gross Profit | 375,000 |
| Operating Income | -16.81M |
| Pretax Income | n/a |
| Net Income | -20.99M |
| EBITDA | -16.02M |
| EBIT | -16.81M |
| Loss Per Share | -$2.32 |
Full Income StatementBalance Sheet
The company has $4.96 million in cash and $4.32 million in debt, giving a net cash position of $639,000 or $0.04 per share.
| Cash & Cash Equivalents | 4.96M |
| Total Debt | 4.32M |
| Net Cash | 639,000 |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | 11.38M |
| Book Value Per Share | 1.13 |
| Working Capital | 663,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.54 million and capital expenditures -$225,000, giving a free cash flow of -$15.77 million.
| Operating Cash Flow | -15.54M |
| Capital Expenditures | -225,000 |
| Free Cash Flow | -15.77M |
| FCF Per Share | -$0.97 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -4,483.47% |
| Pretax Margin | -4,389.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iBio, Inc. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -376.23% |
| Shareholder Yield | -376.23% |
| Earnings Yield | -177.30% |
| FCF Yield | -133.17% |
Analyst Forecast
The average price target for iBio, Inc. is $4.87, which is 567.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.87 |
| Price Target Difference | 567.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -31.30% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 29, 2023. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Nov 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
iBio, Inc. has an Altman Z-Score of -24.99 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -24.99 |
| Piotroski F-Score | 2 |
